Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Gains from Sales and Divestitures (2017 - 2026)

Updated

Coherus Oncology (CHRS) recorded Gains from Sales and Divestitures of -$110,000 in Q4 2019, compared with $1,000 a year earlier.

Analysis

Coherus Oncology (CHRS) Gains from Sales and Divestitures (2017 - 2026) Analysis & Trends

  • Across earlier years, Gains from Sales and Divestitures came in at -$3.86 million in FY2018, -$558,000 in FY2017, $6,000 in FY2016 and -$382,000 in FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -311,000.00
Mar 31, 2026 -388,000.00
Dec 31, 2025 -365,000.00
Sep 30, 2025 -422,000.00
Dec 31, 2024 -57,000.00
Sep 30, 2024 -1.09 Mn
Jun 30, 2024 24.09 Mn
Mar 31, 2024 153.65 Mn
Dec 31, 2019 -110,000.00
Dec 31, 2018 1,000.00
Dec 31, 2017 -94,000.00
API Access

Coherus Oncology Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CHRS&period=max&api_key=YOUR_API_KEY